ブース番号3H-32
カテゴリー原料
Andros Pharmaceuticals Co., Ltd.
小間番号：3H-32
カテゴリー：原料
企業情報
TEL：
住所： 6F., No.22, Sec.2, ShengYi Rd., Zhubei City, Hsinchu County, Hsinchu Science Park
URL：
http://
Andros Pharmaceuticals is a Clinical-stage company dedicated to developing TOPICAL new dosage form using its proprietary technology - Superior Skin Sorption System (S4). Andros is supported by a multidisciplinary R&D team and a PIC/S GMP facility, enabling the company to maintain solid quality control, and provide comprehensive drug development from bench to commercialization.
(1) APC 101, Topical 5% Lidocaine spray indicated for post-herpetic neuralgia with Phase I/IIa completed.
(2) APC 201, Topical 4% Diclofenac solution foam indicated for knee osteoarthritis (OA) with Phase I/IIa completed.
Andros also has super generic products including local anesthesia cream, minoxidil solution and LipoT4N5 launched in Taiwan.
(1) APC 101, Topical 5% Lidocaine spray indicated for post-herpetic neuralgia with Phase I/IIa completed.
(2) APC 201, Topical 4% Diclofenac solution foam indicated for knee osteoarthritis (OA) with Phase I/IIa completed.
Andros also has super generic products including local anesthesia cream, minoxidil solution and LipoT4N5 launched in Taiwan.
企業情報
| 住所 | 6F., No.22, Sec.2, ShengYi Rd., Zhubei City, Hsinchu County, Hsinchu Science Park |
|---|---|
| URL | http:// |
| 出展製品・サービス |
APC 101, Topical 5% Lidocaine spray indicated for post-herpetic neuralgia (PHN) with Phase I and Phase IIa study completed. The Phase IIb/III study was approved by US FDA and AU TGA in 2026, respectively. This registration clinical study is on-going.  APC 201, Topical 4% Diclofenac solution foam indicated for knee osteoarthritis (OA) with Phase I/IIa completed. The result is positive to proceed to Phase IIb/III study which will be ready for IND submission in Q2, 2026. LALP Cream, Topical cream of 2.5% Lidocaine and 2.5% Prilocaine mixture, formulated as an oil-in-water emulsion, and is used widely in dermal analgesic applications such as intravenous catheter placement and venipuncture. LALP Cream is manufactured via a proprietary process with a strict quality control over raw materials. LALP Cream received TFDA license (no. 058568) and is currently on market. LTC Cream, Topical cream of 7% Lidocaine and 7% Tetracaine mixture, and is used widely in local anesthesia for superficial dermatological procedures such as skin filling injections, pulsed dye laser therapy, facial laser resurfacing, and laser tattoo removal. LTC Cream is manufactured via a proprietary process with strict quality control. LTC cream is the highest concentration for the combination of local anesthetics on market. LTC Cream received TFDA license (no. 061895). iMinos Solution, Topical solution (available in 2% and 5%) is indicated for Alopecia Androgenetica (baldness). The product highlights low irritation and high skin permeation. iMinos Solution 2% and 5% received TFDA license (no. 059889, 059890) and is currently on market. T4 endonuclease V (T4N5), 16 kDa protein with the ability to repair DNA damage. Long-term skin exposure to the UV radiation can induce Thymine (T) bases in DNA to form lesions known as T-T dimer, which ages the skin and can be carcinogenic. T4N5 removes the T-T dimer and allows DNA to replicate normally, restoring healthy skin conditions. T4N5 also possesses anti-wrinkle, and anti-sunburn/photo damage capabilities. Because hydrophilicity and large molecular weight limit the permeation of T4N5, b |
|---|
出展製品・サービス
APC 101, Topical 5% Lidocaine spray indicated for post-herpetic neuralgia (PHN) with Phase I and Phase IIa study completed. The Phase IIb/III study was approved by US FDA and AU TGA in 2026, respectively. This registration clinical study is on-going.APC 201, Topical 4% Diclofenac solution foam indicated for knee osteoarthritis (OA) with Phase I/IIa completed. The result is positive to proceed to Phase IIb/III study which will be ready for IND submission in Q2, 2026.LALP Cream, Topical cream of 2.5% Lidocaine and 2.5% Prilocaine mixture, formulated as an oil-in-water emulsion, and is used widely in dermal analgesic applications such as intravenous catheter placement and venipuncture. LALP Cream is manufactured via a proprietary process with a strict quality control over raw materials. LALP Cream received TFDA license (no. 058568) and is currently on market.LTC Cream, Topical cream of 7% Lidocaine and 7% Tetracaine mixture, and is used widely in local anesthesia for superficial dermatological procedures such as skin filling injections, pulsed dye laser therapy, facial laser resurfacing, and laser tattoo removal. LTC Cream is manufactured via a proprietary process with strict quality control. LTC cream is the highest concentration for the combination of local anesthetics on market. LTC Cream received TFDA license (no. 061895).iMinos Solution, Topical solution (available in 2% and 5%) is indicated for Alopecia Androgenetica (baldness). The product highlights low irritation and high skin permeation. iMinos Solution 2% and 5% received TFDA license (no. 059889, 059890) and is currently on market.T4 endonuclease V (T4N5), 16 kDa protein with the ability to repair DNA damage. Long-term skin exposure to the UV radiation can induce Thymine (T) bases in DNA to form lesions known as T-T dimer, which ages the skin and can be carcinogenic. T4N5 removes the T-T dimer and allows DNA to replicate normally, restoring healthy skin conditions. T4N5 also possesses anti-wrinkle, and anti-sunburn/photo damage capabilities. Because hydrophilicity and large molecular weight limit the permeation of T4N5, b